NCT02653625已完成2 期
PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 9
- 主要终点
- Percentage Change From Baseline Through Week 24 in Serum Alkaline Phosphatase (ALP)
研究概览
简要总结
This is an open label, proof of concept (PoC) study of Cenicriviroc (CVC) in adult participants with Primary Sclerosing Cholangitis (PSC). The main objective of this PoC study is to assess changes in alkaline phosphatase (ALP) both individually and as a group, over 24 weeks of treatment with CVC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants with chronic cholestatic liver disease for at least 6 months
- •Clinical diagnosis of Primary Sclerosing Cholangitis (PSC) as evident by chronic cholestasis of more than six months duration with either a consistent magnetic resonance cholangiopancreatography (MRCP)/endoscopic retrograde cholangiopancreatography (ERCP) showing sclerosing cholangitis, or a liver biopsy taken at any time consistent with PSC in the absence of a documented alternative etiology for sclerosing cholangitis. If diagnosis of PSC was made by histology alone, it must require the presence of fibro-obliterative lesions (i.e., onion skin lesions)
- •Participants with or without Inflammatory Bowel Disease (IBD) are allowed. If participant has IBD, documented evidence of IBD either by prior endoscopy or in previous medical records, for ≥ 6 months. In addition, participants will be required to enter the study with a Partial Mayo Risk score of 0-3, inclusively
- •In participants receiving treatment with ursodeoxycholic acid (UDCA), therapy must be stable for at least 3 months, and at a dose not greater than 20 mg/kg/day
- •Serum ALP greater than 1.5 × upper limit of normal (ULN)
- •Ability to understand and sign a written informed consent form (ICF)
- •Participants receiving allowed concomitant medications need to be on stable therapy for 28 days prior to the Baseline Visit with the exception of UDCA in which participants need to be on stable therapy for ≥ 3 months
排除标准
- •Presence of documented secondary sclerosing cholangitis (such as ischemic cholangitis, recurrent pancreatitis, intraductal stone disease, severe bacterial cholangitis, surgical or blunt abdominal trauma, recurrent pyogenic cholangitis, choledocholithiasis, toxic sclerosing cholangitis due to chemical agents, or any other cause of secondary sclerosing cholangitis) on prior clinical investigations
- •Small duct PSC
- •Presence of percutaneous drain or bile duct stent
- •History of cholangiocarcinoma or high clinical suspicion over dominant stricture within 1 year by MRCP/ERCP or clinical judgment
- •Ascending cholangitis within 60 days prior to Screening
- •Alcohol consumption greater than 21 units/week for males or 14 units/week for females (one unit of alcohol is ½ pint of beer [285 mL], 1 glass of spirits [25 mL] or 1 glass of wine [125 mL])
- •Prior or planned liver transplantation
- •Presence of alternative causes of chronic liver disease, including alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, autoimmune hepatitis
- •History of cirrhosis and/or hepatic impairment (Child-Pugh classes A, B and C) and/or hepatic decompensation including ascites, encephalopathy or variceal bleeding. Participants who show evidence of significant worsening of hepatic function will be excluded
- •Participants with fibrosis evidence of cirrhosis, as determined by local transient elastography (TE, e.g., Fibroscan) values of ≥ 13.0 kPa, taken within the last 6 months. If TE has not been conducted within the 6 months prior to screening, then one will be conducted during the screening period and can be used as the Baseline value.
- •Moderate to Severe active IBD or flare in colitis activity within the last 90 days requiring intensification of therapy beyond Baseline treatment. Participants with stable mild to moderate IBD, who are on treatment, are allowed provided they are stable for 3 months with 5-amino salicylic acid drugs or Azathioprine (allowed dose of azathioprine is 50-200 mg/day)
- •Use of oral prednisolone > 10 mg/day, biologics and/or hospitalization for colitis within 90 days are disallowed
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT); above the allowed cut-offs, as determined by Screening values:
- •AST > 200 IU/L males and females
- •ALT: males > 250 IU/L and females > 200 IU/L
- •Total Bilirubin and Direct Bilirubin; above the allowed cut-offs, as determined by Screening values:
- •Total Bilirubin > 2.0 mg/dL
- •Direct Bilirubin > 0.8 mg/dL
- •International normalized ratio > 1.3 in the absence of anticoagulants
- •Immunoglobulin G4 (IgG4) > 4 × ULN at Screening or evidence of IgG4-related sclerosing cholangitis
- •Females who are pregnant or breastfeeding
- •Any other clinically significant disorders or prior therapy that, in the opinion of the investigator, would make the participant unsuitable for the study or unable to comply with the dosing and protocol requirements
研究组 & 干预措施
Cenicriviroc 150 mg
Experimental
One tablet of Cenicriviroc 150 mg once daily with food in the morning for 24 weeks.
干预措施: Cenicriviroc 150 mg (Drug)
结局指标
主要结局
Percentage Change From Baseline Through Week 24 in Serum Alkaline Phosphatase (ALP)
时间窗: Baseline (Day 1) to Week 24
ALP was used as a primary surrogate marker for measuring Primary Sclerosing Cholangitis disease. The percent change from Baseline was defined as 100\*(value at each visit - Baseline value)/Baseline value. The Baseline value was defined as the last non-missing value on or before the Baseline visit (Day 1). A negative percentage change from baseline indicates an improvement.
次要结局
- Percentage of Participants Who Normalized ALP at Week 24(Week 24)
- Percentage of Participants Who Discontinued Due to a TEAE(Baseline (Day 1) to Week 24)
- Percentage of Participants Who Achieved Serum ALP of Less Than 1.5 Times Upper Limit of Normal (ULN) in Serum ALP at Week 24(Week 24)
- Percentage of Participants Who Achieved a 50% Decrease in ALP at Week 24(Week 24)
- Percentage of Participants With a Treatment-emergent Adverse Event (TEAE)(Baseline (Day 1) to Week 24)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
2 期
A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnTHeart Failure With Preserved Ejection FractionNCT04766892Bristol-Myers Squibb30
已完成
2 期
A Study Investigating the Efficacy and Safety of Sepranolone in Women With Menstrual MigraineMenstrual MigraineNCT04102995Asarina Pharma86
已完成
不适用
A Proof of Concept Clinical Study to Investigate the Effects of an Experimental Cosmetic Moisturiser on the Barrier Function of Human Skin on the Face and ForearmSkin CareNCT03216265GlaxoSmithKline69
撤回
2 期
SOM230 Ectopic ACTH-producing TumorsEctopic ACTH SyndromeNCT02780882Cedars-Sinai Medical Center
招募中
2 期
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease PatientsMild, Moderate, or Severe Alzheimer's DiseaseNCT06745583Elixiron Immunotherapeutics Inc.15